Making sense of cephalosporin and amoxicillin/clavulanate susceptibility testing for uropathogens

Clinical Infectious Diseases

Volumn 59, Issue 9, 2014, Pages 1349-1350

  Nguyen, Hien M ^a   Labreche, Matthew J ^a   Graber, Christopher J ^b  

^a KAISER PERMANENTE   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAZOLIN; CEFDINIR; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; LORACARBEF; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; DRUG BLOOD LEVEL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; LABORATORY TEST; LETTER; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PYELONEPHRITIS; SERUM; URINARY TRACT INFECTION; DRUG EFFECTS; ENTEROCOCCUS FAECALIS; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; HUMANS; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTIONS;

EID: 84913603929     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu574     Document Type: Letter

References (9)

1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
2. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002; 19:546-53.
3. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 4. Available at: http://www.eucast.org. Accessed 1 June 2014.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 24th informational supplement. CLSI document M100-S24. Wayne, PA: CLSI, 2014.
5. Tamma PD, Sklansky DJ, Palazzi DL, Swamy S, Milstone AM. Antibiotic suceptibility of common pediatric uropathogens in the United States. Clin Infect Dis 2014; 59:1351.
6. Schuetz AN, Brasso WB, Crandon JL, et al. Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae. Diagn Microbiol Infect Dis 2013; 77:381-2.
7. Nguyen HM, Graber CJ. Cephalothin susceptibility testing as class representative for oral cephalosporins: is it time to move on? Diagn Microbiol Infect Dis 2013; 76:483-5.
8. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillinclavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005; 293: 949-55.
9. Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extendedspectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2014; 69:871-80.